US FDA's Dietary Supplement Programs Deserve A Raise, Trade Groups Tell Senate Appropriators
Executive Summary
Compliant industry drove US market growth to $55bn in 2020, and faster growth and higher sales are ahead if FDA’s Office of Dietary Supplement Programs has sufficient funding to eliminate non-compliant businesses.
You may also be interested in...
Honey Sachets Are Latest Sweet Spot For Selling Products With Undisclosed ED Drugs In US
FDA's warnings to four companies selling honey sachets containing undisclosed ED ingredients are latest examples of businesses marketing noncompliant products because the agency doesn't have sufficient funding to regulate the market, says University of Connecticut pharmacy professor Michael White.
US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace
CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.
Regulation Of US Supplement Industry Needs ‘Really Hard Look’ – FDA's Woodcock
Acting commissioner's comment on supplement industry regulation was her most definitive statement about the agency’s work in consumer health sector at CHPA's regulatory conference. Pandemic, she says, heightened consumer interest in self-care along with demand for OTC drugs and supplements.